This 56-week, randomized, placebo-controlled trial assessed the efficacy and safety of controlled-release phentermine/topiramate (PHEN/TPM CR) in 1,267 adults with class II or III obesity (BMI ≥35 kg/m²). Participants were randomized to receive placebo, PHEN/TPM CR 3.75/23 mg, or PHEN/TPM CR 15/92 mg, alongside a reduced-calorie diet. At week 56, mean
